Penal Reform International launch an event for Global Prison Trends 2020, international leaders and experts which will address chronic issues that have led to this human rights and public health crisis with people in prison being so vulnerable – and will question how we should respond, now and in the long-term.
WHO, UNODC and experts NGOs created this second webinar to discuss practical matters related to OST, overdose, non-injecting drug use programmes and advocacy opportunities.
The event will bring together scientists, policy makers, healthcare professionals, people most affected by COVID-19, funders, media and community to discuss breaking COVID-19 research, policy analysis and frontline experience
The webinar hosted by Correlation - European Harm Reduction Network aims to assess the effects of the current COVID-19 crisis on the functioning of drug consumption rooms.
Correlation - European Harm Reduction Network's webinar will explore the challenges posed by the pandemic in providing support and information to the most vulnerable groups of people who use drugs.
This online discussion hosted by LSE will provide an overview of the impact of the pandemic on drug markets and its consequences for people who use drugs and policy makers.
The roundtable will be an opportunity for civil society and communities to learn about the Global Fund response to the pandemic through grant flexibilities and to share good practices.
The event aims to raise awareness for the commitments made in 1995 in Beijing and to discuss how the COVID-19 pandemic is affecting women and girls and further deepening pre-existing inequalities.
This third webinar is aimed at discussing harm reduction services for non-injecting drug users and particularly people who use stimulant drugs in the time of COVID-19.
The webinar will discuss the impact of lockdown restrictions on vulnerable groups and provide recommendations for an appropriate response to the pandemic.
This webinar will address access to opioid treatment services during the pandemic and opportunities to build on recent changes to federal regulations that have made buprenorphine and methadone prescribing more flexible and accessible.
